Does Blue Cross Blue Shield Cover Skyrizi for Crohn's?

If your gastroenterologist has prescribed Skyrizi for Crohn's disease and you carry a Blue Cross Blue Shield card, the honest answer to whether your plan covers it is that it depends on which Blue plan you have. Blue Cross Blue Shield is not a single insurer. It is a federation of 33 independent, locally operated companies that license the Blue Cross and Blue Shield names for specific geographic areas. Each company writes its own coverage policies, runs its own drug list, and contracts with its own pharmacy benefit manager. A neighbor on a different Blue plan can have completely different rules from yours. Most Blue plans do cover Skyrizi for Crohn's, but nearly all of them place conditions on that coverage, and those conditions are where approvals stall.

What Skyrizi Is and Why Plans Scrutinize It

Skyrizi, the brand name for risankizumab, is an interleukin-23 inhibitor that the FDA approved for moderately to severely active Crohn's disease in adults in 2022. According to the FDA prescribing information, the regimen uses an intravenous induction dose of 600 mg given at weeks 0, 4, and 8, followed by subcutaneous maintenance injections of 180 mg or 360 mg starting at week 12 and continuing every 8 weeks. The approval rested on the phase 3 ADVANCE and MOTIVATE induction trials and the FORTIFY maintenance trial, both published in The Lancet in 2022. Skyrizi is an expensive specialty biologic, so plans apply prior authorization and utilization controls to it. That scrutiny is normal and predictable, and understanding it is the first step to clearing it.

The Coverage Answer Depends on Your Specific Blue Plan

Because each Blue company operates on its own, there is no single Blue Cross Blue Shield Skyrizi rule. One element that varies is the pharmacy benefit manager. Some Blue plans contract with Prime Therapeutics, which Horizon Blue Cross Blue Shield of New Jersey names as its pharmacy partner. Others use CarelonRx or a different manager, and the PBM shapes the drug list and the prior authorization process. Another variable is how the benefit splits. Skyrizi's IV induction is typically billed under the medical benefit because a provider administers it, while the subcutaneous maintenance pens often run through the pharmacy benefit. That split can mean two separate authorizations. Tier placement, copay structure, and step requirements differ by plan and state, so no one can promise you a guaranteed tier or out-of-pocket cost in advance.

Step Therapy and Prior Authorization Criteria to Expect

Most Blue plans gate Skyrizi behind step therapy, meaning you must show that less expensive treatments failed first. A concrete example comes from the published Blue Cross Blue Shield of Michigan medical policy for Skyrizi IV, which requires a Crohn's diagnosis plus documentation that conventional therapy was ineffective, contraindicated, or not tolerated. The policy gives examples such as steroids for at least 7 days and an immunomodulator like azathioprine for at least 2 months. It also requires trial and failure of the plan's preferred drugs listed in its utilization management documents, which often means a preferred anti-TNF agent. These criteria reflect the framework in the 2021 American Gastroenterological Association guidelines on moderate to severe Crohn's disease, which support biologic therapy for disease that does not respond to conventional treatment. Your own plan may word its criteria differently, so the specifics in your medical policy govern your case.

How to Find Your Plan's Skyrizi Policy and Formulary

You do not have to guess at your rules. Your member ID card names your specific Blue company, and that company publishes the documents you need. Start with two things.

• Your plan's drug formulary, which shows whether Skyrizi is covered, on which tier, and under which benefit

• Your plan's medical or pharmacy policy for risankizumab, which lists the exact prior authorization and step therapy criteria

You can usually find both by logging into your member portal or searching your Blue company's provider site for its medical drug policies. Your gastroenterologist's office and the specialty pharmacy can also pull your plan's requirements. Reading the actual policy before submission lets your physician build the prior authorization to match it, which reduces the back-and-forth that delays starting therapy.

Building the Medical-Necessity Case and Appealing a Denial

The strongest prior authorization request maps your history directly onto your plan's criteria. That means documenting each prior therapy by name, dose, duration, and the reason it failed or was stopped, along with disease activity evidence such as endoscopy findings, imaging, or biomarkers. When a Blue plan denies Skyrizi, the denial letter cites a specific reason, often an unmet step requirement or missing documentation, and you have the right to appeal. A focused appeal addresses that exact reason, supplies the missing records, and includes a physician letter of medical necessity that ties your case to the plan's own language and to the FDA-approved indication and the trial evidence. Contraindications to a required step drug, prior intolerance, or urgent disease severity can support an exception or an expedited review. Persistence matters, because initial denials on specialty biologics are frequently overturned when the complete clinical picture is presented.

The Bottom Line on Blue Cross Coverage for Skyrizi

Blue Cross Blue Shield generally covers Skyrizi for Crohn's disease, but coverage is conditional and plan-specific rather than automatic. The drug is FDA-approved for Crohn's and backed by phase 3 evidence, which gives you firm ground to stand on, yet your particular Blue company controls the formulary tier, the benefit split, the pharmacy benefit manager, and the step therapy you must satisfy. The reliable path is to read your own plan's formulary and risankizumab medical policy, document your full treatment history against those criteria, and submit a prior authorization built to match. If a denial comes, treat it as a step in the process rather than a final answer, and appeal it with the specific records the policy asks for.